Contribute Try STAT+ Today

It’s tempting to interpret the Food and Drug Administration’s surprise rejections of drugs from Gilead Sciences and Biomarin Pharmaceuticals this week as an agency-wide sentiment downshift, raising concerns that fewer new medicines will reach the market.

Don’t make that mistake.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Agreed Suze, in the lofty days string of continuous new HIV drugs approvals, Gilead worked closely with the FDA and tweaked the clinical study protocols to optiwhat the FDA was looking for in terms of convincing evidence of efficacy and safety. It seems sadly, the current regime could no longer do that.

  • It we ould be fantastic if Adam can ask O’Day for an interview and get the comments from Gilead’s misfiring and fumbling CEO.

  • With certainty, these companies knew at least 3-4 weeks prior to their PDUFA because there would have been radio-silence with respect to labeling discussions and PMRs. So they knew it was going south. In fact look at BioMarins stock price over the 30 days before they got their CRL.

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy